Exploration of the Mechanism of Action of in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation.
[PURPOSE] The anti-tumor effects of , as a medicinal and dietary Chinese medicine, have long been documented.
APA
Zhan S, Lu X, et al. (2025). Exploration of the Mechanism of Action of in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation.. Journal of hepatocellular carcinoma, 12, 1973-1990. https://doi.org/10.2147/JHC.S527095
MLA
Zhan S, et al.. "Exploration of the Mechanism of Action of in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation.." Journal of hepatocellular carcinoma, vol. 12, 2025, pp. 1973-1990.
PMID
40904605
Abstract
[PURPOSE] The anti-tumor effects of , as a medicinal and dietary Chinese medicine, have long been documented. However, the mechanism of action for its therapeutic effect has not been fully elucidated.
[METHODS] The chemical constituents of were screened using PubMed, CNKI, and Wanfang databases. Swiss Target Prediction was used to predict ingredient targets, while liver cancer targets were obtained from multiple databases. Venny 2.1.0 software identified intersection genes between the drug and disease, and a Protein-Protein Interaction (PPI) network was constructed. The DAVID database was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Following this, the compound molecules were docked onto the core targets, and a visual analysis was conducted. The network pharmacology results were experimentally validated through in vitro studies with HepG2 cells.
[RESULTS] The study identified 17 core components and 374 ingredient targets, with 1,249 disease targets collected from databases, yielding 50 overlapping targets. GO analysis revealed 284 Biological Process (BP) terms, 38 Cellular Component (CC) terms, and 75 Molecular Function (MF) terms. KEGG enrichment highlighted key pathways, including Pathways in cancer, PI3K-AKT signaling, Prostate cancer, and Proteoglycans in cancer. Molecular docking showed strong activity of Butin, Skimmin, and N-p-Coumaroyltyramine with core targets AKT1, EGFR, and CCND1. In vitro experiments demonstrated that aqueous extracts significantly inhibited HepG2 cell proliferation. Western blotting analysis further revealed that the extracts downregulated the expression levels of p-PI3K, PI3K, AKT1, EGFR, and CCND1 proteins.
[CONCLUSION] The key active components of in treating liver cancer include butin, skimmin, and N-p-coumaroyltyramine, etc. The specific mechanism of action may be related to the modulation of targets such as p-PI3K/PI3K, AKT1, EGFR, and CCND1, and signaling pathways such as PI3K-Akt.
[METHODS] The chemical constituents of were screened using PubMed, CNKI, and Wanfang databases. Swiss Target Prediction was used to predict ingredient targets, while liver cancer targets were obtained from multiple databases. Venny 2.1.0 software identified intersection genes between the drug and disease, and a Protein-Protein Interaction (PPI) network was constructed. The DAVID database was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Following this, the compound molecules were docked onto the core targets, and a visual analysis was conducted. The network pharmacology results were experimentally validated through in vitro studies with HepG2 cells.
[RESULTS] The study identified 17 core components and 374 ingredient targets, with 1,249 disease targets collected from databases, yielding 50 overlapping targets. GO analysis revealed 284 Biological Process (BP) terms, 38 Cellular Component (CC) terms, and 75 Molecular Function (MF) terms. KEGG enrichment highlighted key pathways, including Pathways in cancer, PI3K-AKT signaling, Prostate cancer, and Proteoglycans in cancer. Molecular docking showed strong activity of Butin, Skimmin, and N-p-Coumaroyltyramine with core targets AKT1, EGFR, and CCND1. In vitro experiments demonstrated that aqueous extracts significantly inhibited HepG2 cell proliferation. Western blotting analysis further revealed that the extracts downregulated the expression levels of p-PI3K, PI3K, AKT1, EGFR, and CCND1 proteins.
[CONCLUSION] The key active components of in treating liver cancer include butin, skimmin, and N-p-coumaroyltyramine, etc. The specific mechanism of action may be related to the modulation of targets such as p-PI3K/PI3K, AKT1, EGFR, and CCND1, and signaling pathways such as PI3K-Akt.
같은 제1저자의 인용 많은 논문 (5)
- [Expression of Concern] MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA.
- Intranasal immunization of recombinant vaccinia virus bearing FeLV SU elicits systemic and mucosal immunity.
- [Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance].
- Building and validating a machine learning-based survival prediction model for early gastric cancer: a SEER database analysis.
- PER2 knockdown drives immunotherapy resistance in gastric cancer via metabolic reprogramming of myeloid-derived suppressor cells.